Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lucira Health

An at-home COVID-19 and flu test gets FDA emergency use authorization

The Food and Drug Administration has approved an at-home test that can detect and discern between COVID-19 infection and two strains of the flu, Influenza A and B, continuing the shift from clinical to home-diagnostic care that blossomed during the height of the pandemic.

Tribune News Service

FDA authorizes first at-home combination test for COVID and flu

FDA authorizes first at-home combination test for COVID and flu

The Lucira COVID-19 and Flu Home Test is a single-use test, which can be purchased without a prescription.

Chicago Sun-Times

FDA authorizes the first at-home test for COVID-19 and the flu

FDA authorizes the first at-home test for COVID-19 and the flu

The at-home nasal swab kit simultaneously tests for COVID-19 and two strains of the flu.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

12 Health Care Stocks Moving In Thursday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Lucira Health: Q1 Earnings Insights

Lucira Health: Q1 Earnings Insights

Lucira Health (NASDAQ:LHDX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lucira Health beat estimated earnings by 600.0%, reporting an EPS of $0.4 versus an estimate of $-0.08.

Lucira Health Terminates COVID-19 Test-Related Patent Agreement With Eiken Chemical

Lucira Health Terminates COVID-19 Test-Related Patent Agreement With Eiken Chemical

According to an SEC filing, Lucira Health Inc (NASDAQ:LHDX) has terminated a Patent License with Eiken Chemical Co Ltd, effective May 12, 2022. The Company terminated the agreement because certain Eiken Licensed Patents have expired, all of which are locations in which the Company operates. According to the agreement announced in July 2020,…

Organisations

Food and Drug Administration

Myovant Sciences

Enveric Biosciences

CASI Pharmaceuticals

Avenue rapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

245,662 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play